| DIRECT COMPETITOR COMPARISON | |
| RXII | AGN | MRNA | OPK | Industry | | Market Cap: | 69.85M | 19.29B | 34.65M | 418.68M | 104.49M | | Employees: | 25 | 8,300 | 45 | 61 | 68 | | Qtrly Rev Growth (yoy): | N/A | 3.90% | -84.20% | -62.90% | 19.10% | | Revenue (ttm): | N/A | 4.34B | 14.71M | 7.84M | 13.84M | | Gross Margin (ttm): | N/A | 83.19% | -46.31% | 28.34% | 64.07% | | EBITDA (ttm): | -16.09M | 1.13B | -13.71M | -28.51M | -11.86M | | Oper Margins (ttm): | N/A | 22.21% | -111.05% | -387.49% | -149.46% | | Net Income (ttm): | -16.24M | 561.90M | -19.56M | -31.02M | N/A | | EPS (ttm): | -1.145 | 1.842 | -0.558 | -0.142 | -0.33 | | P/E (ttm): | N/A | 34.45 | N/A | N/A | 17.48 | | PEG (5 yr expected): | N/A | 1.76 | N/A | N/A | 1.35 | | P/S (ttm): | N/A | 4.45 | 2.36 | 53.43 | 10.13 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.66 | 0.00% | 58.36B | 12.58 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 53.27 | 0.00% | 15.41B | 17.83 | | Genzyme Corp. | GENZ | 49.61 | 0.00% | 13.17B | 28.28 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.26 | 0.00% | 38.93B | 16.73 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.70 | 0.00% | 9.40B | 1075.51 | | Teva Pharmaceutical Industries Limited | TEVA | 56.27 | 0.00% | 49.57B | 51.48 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 40.12 | 0.00% | 4.26B | 20.68 | | King Pharmaceuticals Inc. | KG | 12.21 | 0.00% | 3.03B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.69 | 0.00% | 5.71B | 114.66 | | Pfizer Inc. | PFE | 18.63 | 0.00% | 150.34B | 15.47 | | Johnson & Johnson | JNJ | 64.94 | 0.00% | 179.18B | 14.18 | | GlaxoSmithKline plc | GSK | 42.47 | 0.00% | 107.66B | 13.92 | | Sanofi-Aventis | SNY | 40.38 | 0.00% | 105.44B | N/A | | Novartis AG | NVS | 54.75 | 0.00% | 124.35B | 16.39 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 42.88 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 46.76 | 0.00% | 67.80B | 9.39 | | Abbott Laboratories | ABT | 54.53 | 0.00% | 84.34B | 14.77 | | Bristol-Myers Squibb Co. | BMY | 25.95 | 0.00% | 51.41B | 13.42 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AGN | | [video] Health Care Investing in 2010
Mon 11:33am -
at CNBC | | • | AGN | | Top 10 Stocks for Obamacare
Thu, Dec 24 -
at CNBC | | • | MRNA | | MDRNA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Thu, Dec 24 -
EDGAR Online | | • | MRNA | | MDRNA, Inc. Announces Closing of $1 Million Bridge Loan
Thu, Dec 24 -
Marketwire | | • | OPK | | The Next Million-Dollar Penny Stock
Tue, Dec 22 -
at Motley Fool | | • | AGN | | Botox spared over tanning beds in U.S. health fight
Mon, Dec 21 -
at Reuters | | • | AGN | | [$$] Health Care Stocks Can Run Some More
Mon, Dec 21 -
at RealMoney by TheStreet.com | | • | AGN | | Healthcare shares rise as reform bill progresses
Mon, Dec 21 -
Reuters | | • | MRNA | | MDRNA, Inc. Announces Patent Allowance Covering Methods for Targeted siRNA Delivery to the Lung
Thu, Dec 17 -
Marketwire | | • | MRNA | | MDRNA, Inc. Presents Positive Efficacy and Tolerability Data in Non-Human Primates With Proprietary siRNA Compounds
Thu, Dec 3 -
Marketwire | | • | MRNA | | MDRNA, Inc. Presents to International Webinar Audience on Innovations in Oncology Drug Discovery, Development & Delivery
Tue, Dec 1 -
Marketwire | | • | OPK | | OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure
Tue, Nov 17 -
EDGAR Online | | • | OPK | | OPKO Health to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Mon, Nov 16 -
Business Wire | | • | OPK | | OPKO HEALTH, INC. Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | OPK | | OPKO Health Completes Acquisition of NK-1 Compounds from Schering Corporation
Wed, Nov 11 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.26% Nasdaq 0.00%
Competitors
